Cas no 1219795-37-5 (Trimetazidine-d8 DiHCl)
Trimetazidine-d8 DiHCl Chemical and Physical Properties
Names and Identifiers
-
- Trimetazidine-d8 2HCl (piperazine-d8)
- Trimetazidine dihydrochloride salt
- Trimetazidine D8 dihydrochlorideQ: What is Trimetazidine D8 dihydrochloride Q: What is the CAS Number of Trimetazidine D8 dihydrochloride Q: What is the storage condition of Trimetazidine D8 dihydrochloride Q: What are the applications of Trimetazidine D8 dihydrochloride
- Trimetazidine Impurity 1 DiHCl
- Trimetazidine-d
- Trimetazidine-d8 Dihydrochloride
- F91406
- Trimetazidine-d8 (dihydrochloride)
- 2,2,3,3,5,5,6,6-octadeuterio-1-[(2,3,4-trimethoxyphenyl)methyl]piperazine;dihydrochloride
- 1219795-37-5
- CS-0201045
- MS-25339
- HY-B0968S
- Trimetazidine-d8 DiHCl
-
- Inchi： 1S/C14H22N2O3.ClH/c1-17-12-5-4-11(13(18-2)14(12)19-3)10-16-8-6-15-7-9-16;/h4-5,15H,6-10H2,1-3H3;1H
- InChI Key： QHWBCHACIJBSFV-UHFFFAOYSA-N
- SMILES： C(N1C([H])([H])C([H])([H])NC([H])([H])C1([H])[H])C1C=CC(OC)=C(OC)C=1OC.Cl
Computed Properties
- Exact Mass: 346.1666120g/mol
- Monoisotopic Mass: 346.1666120g/mol
- Isotope Atom Count: 8
- Hydrogen Bond Donor Count: 3
- Hydrogen Bond Acceptor Count: 5
- Heavy Atom Count: 21
- Rotatable Bond Count: 5
- Complexity: 259
- Covalently-Bonded Unit Count: 3
- Defined Atom Stereocenter Count: 0
- Undefined Atom Stereocenter Count : 0
- Defined Bond Stereocenter Count: 0
- Undefined Bond Stereocenter Count: 0
- Topological Polar Surface Area: 43?2
Trimetazidine-d8 DiHCl Pricemore >>
| Related Categories | No. | Product Name | Cas No. | Purity | Specification | Price | update time | Inquiry |
|---|---|---|---|---|---|---|---|---|
| TRC | T795612-1mg |
Trimetazidine-d8 Dihydrochloride |
1219795-37-5 | 1mg |
$ 187.00 | 2023-09-05 | ||
| TRC | T795612-10mg |
Trimetazidine-d8 Dihydrochloride |
1219795-37-5 | 10mg |
$ 1454.00 | 2023-09-05 | ||
| MedChemExpress | HY-B0968S-1mg |
Trimetazidine-d |
1219795-37-5 | 99.87 | 1mg |
￥1100 | 2024-07-19 | |
| AN HUI ZE SHENG Technology Co., Ltd. | CS-O-00739-1mg |
1-(2,3,4-trimethoxybenzyl)piperazine-2,2,3,3,5,5,6,6-d8dihydrochloride |
1219795-37-5 | 1mg |
￥1160.00 | 2023-09-15 | ||
| AN HUI ZE SHENG Technology Co., Ltd. | CS-O-00739-10mg |
1-(2,3,4-trimethoxybenzyl)piperazine-2,2,3,3,5,5,6,6-d8dihydrochloride |
1219795-37-5 | 10mg |
￥9060.00 | 2023-09-15 | ||
| 1PlusChem | 1P01CD57-1mg |
Trimetazidine-d8 Dihydrochloride |
1219795-37-5 | ≥99% deuterated forms (d1-d8) | 1mg |
$135.00 | 2023-12-25 | |
| 1PlusChem | 1P01CD57-5mg |
Trimetazidine-d8 Dihydrochloride |
1219795-37-5 | ≥99% deuterated forms (d1-d8) | 5mg |
$358.00 | 2023-12-25 | |
| 1PlusChem | 1P01CD57-10mg |
Trimetazidine-d8 Dihydrochloride |
1219795-37-5 | ≥99% deuterated forms (d1-d8) | 10mg |
$547.00 | 2023-12-25 | |
| 1PlusChem | 1P01CD57-25mg |
Trimetazidine-d8 Dihydrochloride |
1219795-37-5 | ≥99% deuterated forms (d1-d8) | 25mg |
$1056.00 | 2023-12-25 | |
| MedChemExpress | HY-B0968S-5mg |
Trimetazidine-d |
1219795-37-5 | 99.87 | 5mg |
￥4100 | 2024-07-19 |
Trimetazidine-d8 DiHCl Related Literature
-
Huifang Yang,Haoran Guo,Peidong Fan,Xinpan Li,Wenlu Ren,Rui Song Nanoscale, 2020,12, 7024-7034
-
Karl Crowley,Eimer O'Malley,Aoife Morrin,Malcolm R. Smyth,Anthony J. Killard Analyst, 2008,133, 391-399
-
Haitao Li,Yu Pan,Zhizhi Wang,Shan Chen,Ruixin Guo,Jianqiu Chen RSC Adv., 2015,5, 100775-100782
-
Ravi Kumar Yadav,R. Govindaraj Phys. Chem. Chem. Phys., 2020,22, 26876-26886
-
Adeline Huiling Loo,Alessandra Bonanni,Martin Pumera Analyst, 2013,138, 467-471
Additional information on Trimetazidine-d8 DiHCl
Trimetazidine-d8 DiHCl: A Comprehensive Overview
Trimetazidine-d8 DiHCl, also known by its CAS number 1219795-37-5, is a highly specialized compound that has garnered significant attention in the fields of pharmacology and metabolic research. This compound is a deuterated derivative of trimetazidine, a well-known medication used in the treatment of cardiovascular disorders. The addition of deuterium atoms in the form of d8 and the dihydrochloride (DiHCl) salt form introduces unique properties that make it invaluable for advanced research and therapeutic applications.
The primary function of Trimetazidine-d8 DiHCl lies in its ability to modulate cellular energy metabolism. Recent studies have highlighted its role in enhancing mitochondrial efficiency, particularly in conditions where cellular energy demand is heightened, such as ischemic heart disease. The deuterium enrichment in this compound not only stabilizes its molecular structure but also enhances its bioavailability, making it a preferred choice for researchers exploring metabolic pathways.
One of the most promising areas of research involving Trimetazidine-d8 DiHCl is its application in neurodegenerative diseases. Preclinical studies have demonstrated its potential to mitigate oxidative stress and reduce neuronal damage, which are hallmark features of conditions like Alzheimer's disease. The dihydrochloride form of the compound has been shown to improve solubility, thereby facilitating better absorption and distribution within the central nervous system.
In addition to its therapeutic potential, Trimetazidine-d8 DiHCl has become a valuable tool in drug development and pharmacokinetic studies. Its deuterated nature allows researchers to track its metabolism more effectively using advanced analytical techniques such as mass spectrometry. This capability has significantly contributed to our understanding of how drugs are processed and eliminated within the body, paving the way for more efficient drug design.
The synthesis of Trimetazidine-d8 DiHCl involves a multi-step process that ensures high purity and consistency. The incorporation of deuterium atoms is carefully controlled to achieve the desired isotopic enrichment without compromising the compound's pharmacological activity. This rigorous manufacturing process aligns with current Good Manufacturing Practices (cGMP) standards, ensuring that the compound meets the highest quality benchmarks required for both research and clinical use.
From an environmental standpoint, Trimetazidine-d8 DiHCl exhibits favorable biodegradation characteristics, making it a sustainable option for large-scale research applications. Its low toxicity profile further underscores its suitability for use in preclinical models, where minimizing adverse effects is paramount.
In conclusion, Trimetazidine-d8 DiHCl, with its unique chemical properties and versatile applications, represents a significant advancement in medicinal chemistry. As research continues to uncover new insights into its mechanisms of action, this compound is poised to play an increasingly important role in both academic and industrial settings. Its contribution to our understanding of cellular metabolism and disease pathophysiology will undoubtedly shape future therapeutic strategies across various medical disciplines.
1219795-37-5 (Trimetazidine-d8 DiHCl) Related Products
- 5011-34-7(Trimetazidine)
- 13171-25-0(Trimetazidine dihydrochloride)
- 5881-15-2(1-(3-methoxybenzyl)-4-(2,3,4-trimethoxybenzyl)piperazine)
- 1257-19-8(Hexametazidine)
- 53960-20-6(N-Methyl Trimetazidine Dihydrochloride)
- 5882-80-4(Copper,[m-[octahydrogen3,3'-[ureylenebis(p-phenylenecarbonylimino)]bis[7-[(2,8-dihydroxy-3,6-disulfo-1-naphthyl)azo]-8-hydroxy-1,5-naphthalenedisulfonato](4-)]]di-(8CI))
- 5873-55-2(1-(2,3-dimethoxybenzyl)-4-(3-methoxybenzyl)piperazine)
- 159304-24-2((2,3-DIMETHOXY-6[[4-PHENYLMETHYL)-1-PIPERAZINYL]METHYL]PHENOL DIHYDROCHLORIDE)
- 5866-05-7(Pyrrolidine, 1-(tributylgermyl)-)
- 356083-64-2(1-(2,4,5-Trimethoxybenzyl)piperazine)
Audited Supplier
Audited Supplier
Audited Supplier
Audited Supplier
Audited Supplier
